Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AbbVie Halts Brain Tumor Late-Stage Study

AbbVie halted the Phase III INTELLANCE-1 trial of depatuxizumab mafodotin in patients with newly diagnosed glioblastoma whose tumors have epidermal growth factor receptor amplification.

Read More »

Agios Pharma’s Tibsovo Shows Positive Results in Phase III for Another Cancer Indication

Cambridge, Mass.-based Agios Pharmaceuticals announced that Tibsovo (ivosidenib) hit the primary endpoint in the Phase III ClarIDHy trial in patients with cholangiocarcinoma with an isocitrate dehydrogenase 1 mutation.

Read More »

Too much vitamin B6 and B12 tied to hip fractures in older women

Older women who take supplements with high doses of vitamins B6 and B12 may be more likely than their counterparts who do not to experience hip fractures, a U.S. study suggests.

Read More »

A Mathematical Model Makes Earlier Detection of CVD Possible

Early detection of cardiovascular disease is becoming possible due to research from Giovanna Guidoboni, Marjorie Skubic and a team at the University of Missouri.

Read More »

Pfizer’s abrocitinib meets late-stage study goals

Pfizer Inc.’s experimental atopic dermatitis treatment abrocitinib met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease.

Read More »

Zealand Pharma’s Severe Hypoglycemia Treatment Hits the Mark in Another Phase III Trial

Shares of Zealand Pharma A/S were up more than 2 percent after the company announced that dasiglucagon, a potential treatment for severe hypoglycemia, hit the mark in a Phase III study.

Read More »

Myovant Sciences’ uterine fibroids combo therapy meets main goal in study

Myovant Sciences’ combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids.

Read More »

Mallinckrodt Completes Enrollment of Phase 3 Terlipressin CONFIRM Trial

Mallinckrodt plc announced that the company achieved target enrollment of 300 participants in the Phase 3 CONFIRM clinical study to evaluate the efficacy and safety of the investigational agent terlipressin in adult patients with Hepatorenal Syndrome Type 1 (HRS-1).

Read More »

Without heart disease, daily aspirin may be too risky

For people without heart disease, taking a daily aspirin to prevent heart attacks and strokes may increase the risk of severe brain bleeding to the point where it outweighs any potential benefit, a research review suggests.

Read More »

Centogene Launches Two Year Global Parkinson’s Disease Study

Centogene announced the initiation of a 24-month global study to investigate the genetic factors in Parkinson’s disease.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom